ASST. SECTY. FOR HEALTH BRANDT UNDER CONSIDERATION FOR U. TEXAS
ASST. SECTY. FOR HEALTH BRANDT UNDER CONSIDERATION FOR U. TEXAS Medical School (San Antonio) Health Science Center presidency. Brandt is one of "six-to-eight" candidates interviewed for the position by a search cmte. appointed in February by the university's Board of Regents. The regents are scheduled to meet in October to review the search cmte.'s recommendations and select the new president. Under board procedures, the search cmte. would submit its three-to-five top choices to the board for final consideration. Current center president Frank Harrison plans to retire. Brandt, appointed in the early months of the Reagan Administration, has held the asst. secty. post longer than any of his recent predecessors. Surgeon General Koop, appointed in tandem with Brandt, joins the asst. secty. as part of Reagan's old guard at HHS. The selection of Brandt as the Health Science Center president would mean a return to familiar turf for the three and a half year Reagan Administration verteran. Prior to his HHS appointment, Brandt served as University of Texas Vice Chancellor for Health Affairs (1977-1981) and before that as University of Texas Medical Branch at Galveston graduate dean, associate dean for clinical affairs, dean of medicine, and professor of preventive medicine and family medicine (1970-1977).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth